Exhibit 99.1
 | |
 | AmerisourceBergen Corporation |
P.O. Box 959 | |
Valley Forge, PA 19482 | |
AMERISOURCEBERGEN REPORTS
FISCAL 2019 SECOND QUARTER RESULTS
Revenues of $43.3 billion for the Second Quarter, a 5.6 Percent Increase Year-Over-Year
Second Quarter GAAP Diluted EPS of $0.13 and Adjusted Diluted EPS of $2.11
Adjusted Diluted EPS Guidance Range Raised to $6.70 to $6.90 for Fiscal 2019
VALLEY FORGE, PA, May 2, 2019 - AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2019 second quarter ended March 31, 2019, revenue increased 5.6 percent to $43.3 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $0.13 for the March quarter of fiscal 2019, compared to $1.29 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 8.8% to $2.11 in the fiscal second quarter.
The Company raised its adjusted diluted EPS guidance range for fiscal 2019 to $6.70 to $6.90, from $6.65 to $6.85 previously. The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2019 Expectations.
“AmerisourceBergen continues to execute and deliver strong performance with good growth in customer volumes, double-digit Specialty distribution growth and overall strong execution across both the Pharmaceutical Distribution Services and Global Commercialization Services & Animal Health groups this quarter,” said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.
“As we move into the second half of the year, our fiscal 2019 outlook remains strong,” Mr. Collis continued. “AmerisourceBergen continues to be well positioned for long-term growth and we have the utmost confidence that our differentiated strategy and focus on providing innovative services and solutions for our partners will continue to drive sustainable value for all of our stakeholders.”
Second Quarter Fiscal Year 2019 Summary Results
GAAP | Adjusted (Non-GAAP) | |
Revenue | $43.3B | $43.3B |
Gross Profit | $1.4B | $1.3B |
Operating Expenses | $1,377M | $702M |
Operating Income | $48M | $617M |
Interest Expense, Net | $43M | $43M |
Effective Tax Rate | (49.5)% | 21.5% |
Net Income Attributable to ABC | $27M | $449M |
Diluted Earnings Per Share | $0.13 | $2.11 |
Diluted Shares Outstanding | 213M | 213M |
Below, AmerisourceBergen presents descriptive summaries of the Company’s GAAP and adjusted (non-GAAP) quarterly results. In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. For more information related to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information Regarding non-GAAP Financial Measures following the tables.
Second Quarter GAAP Results
• | Revenue: In the second quarter of fiscal 2019, revenue was $43.3 billion, up 5.6 percent compared to the same quarter in the previous fiscal year, reflecting a 5.6 percent increase in Pharmaceutical Distribution Services revenue and a 4.5 percent increase in revenue within Other. Revenue growth is primarily due to the revenue growth of our Pharmaceutical Distribution Services segment. The increase in revenue growth of our Pharmaceutical Distribution Services segment is primarily due to the growth of some of its largest customers, continued strong specialty product sales, and overall market growth. |
• | Gross Profit: Gross profit in the fiscal 2019 second quarter was $1.4 billion, a 13.5 percent increase compared to the same period in the previous fiscal year. Gross profit in the current year quarter was favorably impacted by gains from antitrust litigation settlements and a LIFO credit, and a 4.3 percent increase in Pharmaceutical Distribution Services' gross profit. Pharmaceutical Distribution Services benefited from an increase in revenue, offset in part by PharMEDium's pharmaceutical compounding operations as it shipped fewer units due to the continued implementation of certain remedial measures at its operational locations. Gross profit as a percentage of revenue was 3.29 percent, an increase of 23 basis points from the prior year quarter. |
• | Operating Expenses: In the second quarter of fiscal 2019, operating expenses were $1,377.2 million, compared to $774.3 million in the same period last fiscal year. The significant increase in operating expenses was primarily due to the $570.0 million impairment of PharMEDium's long-lived assets in the quarter. Operating expenses as a percentage of revenue in the fiscal 2019 second quarter was 3.18 percent, compared to 1.89 percent for the same period in the previous fiscal year. |
• | Operating Income: In the fiscal 2019 second quarter, operating income was $47.6 million versus $481.4 million in the prior year quarter. The decrease in operating income was primarily due to the $570.0 million impairment of PharMEDium's long-lived assets, offset in part by an increase in gross profit. Operating income as a percentage of revenue decreased 106 basis points to 0.11 percent in the fiscal 2019 second quarter, compared to the previous fiscal year's second quarter. |
• | Interest Expense, Net: In the fiscal 2019 second quarter, net interest expense of $43.3 million was down 11.0 percent versus the prior year quarter. The decrease from the prior year quarter was primarily due to an increase in interest income. |
• | Effective Tax Rate: The effective tax rate was (49.5) percent for the second quarter of fiscal 2019 and 21.9 percent in the prior year quarter. The effective tax rate in the quarter was primarily impacted by the $570.0 million impairment of PharMEDium's long-lived assets. |
• | Diluted Earnings Per Share: Diluted earnings per share was $0.13 in the second quarter of fiscal 2019 compared to $1.29 in the previous fiscal year’s second quarter. This significant decrease was primarily due to the PharMEDium impairment. |
• | Diluted Shares Outstanding: Diluted weighted average shares outstanding for the second quarter of fiscal 2019 were 212.6 million, a 4.4 percent decline versus the prior fiscal year second quarter, due to share repurchases, net of stock option exercises. |
Second Quarter Adjusted (non-GAAP) Results
• | Revenue: No adjustments were made to the GAAP presentation of revenue. In the second quarter of fiscal 2019, revenue was $43.3 billion, up 5.6 percent compared to the same quarter in the previous fiscal year, reflecting a 5.6 percent increase in Pharmaceutical Distribution Services revenue and a 4.5 percent increase in revenue within Other. Revenue growth is primarily due to the revenue growth of our Pharmaceutical Distribution Services segment. The increase in revenue growth of our Pharmaceutical Distribution Services segment is primarily due to the growth of some of its largest customers, continued strong specialty product sales, and overall market growth. |
• | Adjusted Gross Profit: Adjusted gross profit in the fiscal 2019 second quarter was $1.3 billion, which was up 3.2 percent compared to the same period in the previous year, primarily due to the increase in adjusted gross profit in Pharmaceutical Distribution Services, which was partially offset due to fewer units being shipped by PharMEDium due to the continued implementation of remedial measures at its operational facilities. Adjusted gross profit as a percentage of revenue was 3.04 percent, a decrease of 7 basis points from the prior year quarter. |
• | Adjusted Operating Expenses: In the second quarter of fiscal 2019, adjusted operating expenses were $701.6 million, an increase of 1.5 percent compared to the same period in the last fiscal year, due to an increase in Pharmaceutical Distribution Services segment's expenses, which was partially offset by a decrease in operating expenses in Other. Adjusted operating expenses as a percentage of revenue in the fiscal 2019 second quarter was 1.62 percent, compared to 1.69 percent for the same period in the previous fiscal year. |
• | Adjusted Operating Income: In the fiscal 2019 second quarter, adjusted operating income of $616.7 million increased 5.2 percent from the prior year period due to an increase in operating income within Pharmaceutical Distribution Services which included a favorable impact from Brazil, offset in part by the fewer units being shipped by PharMEDium. Adjusted operating income as a percentage of revenue decreased 1 basis point to 1.42 percent in the fiscal 2019 second quarter compared to the previous fiscal year’s second quarter. |
• | Interest Expense, Net: No adjustments were made to the GAAP presentation of net interest expense. In the fiscal 2019 second quarter, net interest expense of $43.3 million was down 11.0 percent versus the prior year quarter, primarily due to an increase in interest income. |
• | Adjusted Effective Tax Rate: The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2019 and was 20.7 percent in the previous fiscal year’s second quarter. |
• | Adjusted Diluted Earnings Per Share: Adjusted diluted earnings per share was up 8.8 percent to $2.11 in the second quarter of fiscal 2019 compared to $1.94 in the previous fiscal year’s second quarter, driven by the increase in adjusted operating income and a lower share count. |
• | Diluted Shares Outstanding: No adjustments were made to the GAAP presentation of diluted shares outstanding. Diluted weighted average shares outstanding for the second quarter of fiscal 2019 were 212.6 million, a 4.4 percent decline versus the prior fiscal year second quarter, due to share repurchases, net of stock option exercises. |
Segment Discussion
The Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in Other for the purpose of reportable segment presentation. Other consists of operating segments that focus on global commercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI Animal Health (MWI).
Pharmaceutical Distribution Services Segment
Pharmaceutical Distribution Services revenue was $41.7 billion, an increase of 5.6 percent compared to the same quarter in the prior fiscal year primarily due to the growth of some of its largest customers, continued strong specialty product sales, and overall market growth. Segment operating income of $517.0 million in the second quarter of fiscal 2019 was up 5.7 percent compared to the same period in the previous fiscal year, primarily due to the increase in gross profit, offset in part by an increase in operating expenses.
Other
Revenue in Other was $1.7 billion in the second quarter of fiscal 2019, an increase of 4.5 percent compared to the same period in the prior fiscal year, primarily due to ABCS's growth in its Canadian operations and growth at World Courier and MWI. Operating income in Other increased 2.9 percent to $99.9 million in the second quarter of fiscal 2019. This increase was primarily driven by increases in operating income at ABCS's Canadian operations and World Courier.
Recent Company Highlights & Milestones
• | The Healthcare Distribution Alliance honored AmerisourceBergen with the Distribution Management Award for its work on the upcoming Drug Supply Chain Security Act (DSCSA) serialization requirements on verifying serialized pharmaceutical products. |
• | AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation’s premier benchmarking survey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human Rights Campaign Foundation. |
• | AmerisourceBergen opened its newest office located in Carrollton, Texas, and reinforced its commitment to attract and retain unmatched talent in the Texas community. As a part of AmerisourceBergen’s efforts to promote sustainability and employee wellbeing, the new 300,000 sq. ft. facility is actively pursuing a Leadership in Energy and Environmental Design (LEED) Silver certification. |
• | Lash Group, AmerisourceBergen's patient support services business, and AllazoHealth, an artificial intelligence and predictive analytics company focused on ensuring optimal patient outcomes, announced a partnership that will enhance patient adherence and engagement programs through targeted and personalized recommendations that will empower at-risk patients to ultimately make healthier choices. |
• | The AmerisourceBergen Foundation, through its Opioid Resource Grant Program, awarded more than 30 organizations demonstrating community leadership with grants to provide critically needed youth, provider and community education around preventing and addressing prescription medication misuse. |
• | The AmerisourceBergen Foundation announced a $150,000 donation to Southeastern Guide Dogs, a nonprofit focused on transforming lives by creating and nurturing extraordinary partnerships between people and dogs. With the support of this multi-year grant, Southeastern Guide Dogs will be able to increase placements of guide and companion dogs with visually impaired teenagers and children, as well as families of fallen service members and with child advocate professionals in courtrooms. |
• | AmerisourceBergen was named a Philly.com Top Workplace for the 7th year in a row. |
Fiscal Year 2019 Expectations
The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. Please refer to the Supplemental Information Regarding Non-GAAP Financial Measures following the tables for additional information.
Fiscal Year 2019 Expectations on an Adjusted (non-GAAP) Basis
AmerisourceBergen has updated its fiscal year 2019 financial guidance to reflect the Company’s continued solid execution and greater than anticipated number of share repurchases. The company now expects:
• | Adjusted Diluted EPS range raised to $6.70 to $6.90, up from the previous range of $6.65 to $6.85. |
Additional expectations now include:
• | Weighted average diluted shares are now expected to be approximately 214 million, down from the previous expectation of approximately 215 million. |
All other previously communicated aspects of the Company's fiscal year 2019 financial guidance and assumptions remain the same.
Conference Call & Slide Presentation
The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 2, 2019. A slide presentation for investors has also been posted on the Company's website at investor.amerisourcebergen.com. Participating in the conference call will be:
•Steven H. Collis, Chairman, President & Chief Executive Officer
•James F. Cleary, Executive Vice President & Chief Financial Officer
The dial-in number for the live call will be (612) 326-1019. No access code is required. The live call will also be webcast via the Company’s website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.
Replays of the call will be made available via telephone and webcast. A replay of the webcast will be posted on investor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. The telephone replay will also be available approximately two hours after the completion of the call and will remain available for seven days. To access the telephone replay from within the U.S., dial (800) 475-6701. From outside the U.S., dial (320) 365-3844. The access code for the replay is 465792.
Upcoming Investor Events
AmerisourceBergen management will be attending the following investor conference in the coming months:
•Goldman Sachs 40th Annual Global Healthcare Conference, June 11-13, Rancho Palos Verdes, CA.
Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 21,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500, with more than $160 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at investor.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. These statements are not guarantees of future performance and are based on assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in pharmaceutical market growth rates; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; increased public concern over the abuse of opioid medications; prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action, including a consent decree, in connection with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business; suspension of production of CSPs, including continued suspension at our Memphis facility; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; the loss, bankruptcy or insolvency of a major supplier; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the Company’s operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations or PharMEDium), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of H. D. Smith and PharMEDium, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the fact the acquisition of H. D. Smith may make it more difficult to establish or maintain relationships with employees, suppliers, customers and other business partners; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2018 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.
AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY
(In thousands, except per share data)
(unaudited)
Three Months Ended March 31, 2019 | % of Revenue | Three Months Ended March 31, 2018 | % of Revenue | % Change | ||||||||||
Revenue | $ | 43,319,602 | $ | 41,033,858 | 5.6% | |||||||||
Cost of goods sold | 41,894,846 | 39,778,175 | 5.3% | |||||||||||
Gross profit 1 | 1,424,756 | 3.29% | 1,255,683 | 3.06% | 13.5% | |||||||||
Operating expenses: | ||||||||||||||
Distribution, selling, and administrative | 628,036 | 1.45% | 617,426 | 1.50% | 1.7% | |||||||||
Depreciation and amortization | 123,766 | 0.29% | 119,388 | 0.29% | 3.7% | |||||||||
Employee severance, litigation, and other 2 | 55,389 | 37,449 | ||||||||||||
Impairment of long-lived assets 3 | 570,000 | — | ||||||||||||
Total operating expenses | 1,377,191 | 3.18% | 774,263 | 1.89% | 77.9% | |||||||||
Operating income | 47,565 | 0.11% | 481,420 | 1.17% | (90.1)% | |||||||||
Other (income) loss 4 | (14,494 | ) | 29,123 | |||||||||||
Interest expense, net | 43,275 | 48,637 | (11.0)% | |||||||||||
Loss on consolidation of equity investments | — | 42,328 | ||||||||||||
Income before income taxes | 18,784 | 0.04% | 361,332 | 0.88% | (94.8)% | |||||||||
Income tax (benefit) expense | (9,289 | ) | 79,172 | |||||||||||
Net income | 28,073 | 0.06% | 282,160 | 0.69% | (90.1)% | |||||||||
Net (income) loss attributable to noncontrolling interest | (938 | ) | 5,295 | |||||||||||
Net income attributable to AmerisourceBergen Corporation | $ | 27,135 | 0.06% | $ | 287,455 | 0.70% | (90.6)% | |||||||
Earnings per share: | ||||||||||||||
Basic | $ | 0.13 | $ | 1.31 | (90.1)% | |||||||||
Diluted | $ | 0.13 | $ | 1.29 | (89.9)% | |||||||||
Weighted average common shares outstanding: | ||||||||||||||
Basic | 210,934 | 219,200 | (3.8)% | |||||||||||
Diluted | 212,563 | 222,303 | (4.4)% | |||||||||||
________________________________________
1 | Includes a $66.8 million LIFO credit, a $52.0 million gain from antitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019. Includes $22.5 million of PharMEDium remediation costs and a $0.3 million gain from antitrust litigation settlements in the three months ended March 31, 2018. |
2 | Includes $14.0 million of employee severance, $13.8 million of litigation costs primarily related to opioid lawsuits and investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2019. Includes $20.8 million of employee severance, $7.6 million of litigation costs primarily related to opioid lawsuits and investigations, and $9.0 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2018. |
3 | Impairment of finite-lived intangible assets and property and equipment relating to PharMEDium. |
4 | Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019. Includes a $30.0 million impairment on a non-customer note receivable in the three months ended March 31, 2018. |
AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY
(In thousands, except per share data)
(unaudited)
Six Months Ended March 31, 2019 | % of Revenue | Six Months Ended March 31, 2018 | % of Revenue | % Change | ||||||||||
Revenue | $ | 88,712,054 | $ | 81,500,190 | 8.8% | |||||||||
Cost of goods sold | 85,989,718 | 79,131,855 | 8.7% | |||||||||||
Gross profit 1 | 2,722,336 | 3.07% | 2,368,335 | 2.91% | 14.9% | |||||||||
Operating expenses: | ||||||||||||||
Distribution, selling, and administrative | 1,284,621 | 1.45% | 1,175,948 | 1.44% | 9.2% | |||||||||
Depreciation and amortization | 246,266 | 0.28% | 224,524 | 0.28% | 9.7% | |||||||||
Employee severance, litigation, and other 2 | 96,061 | 67,470 | ||||||||||||
Impairment of long-lived assets 3 | 570,000 | — | ||||||||||||
Total operating expenses | 2,196,948 | 2.48% | 1,467,942 | 1.80% | 49.7% | |||||||||
Operating income | 525,388 | 0.59% | 900,393 | 1.10% | (41.6)% | |||||||||
Other (income) loss 4 | (11,397 | ) | 29,447 | |||||||||||
Interest expense, net | 85,445 | 84,501 | 1.1% | |||||||||||
Loss on consolidation of equity investments | — | 42,328 | ||||||||||||
Loss on early retirement of debt | — | 23,766 | ||||||||||||
Income before income taxes | 451,340 | 0.51% | 720,351 | 0.88% | (37.3)% | |||||||||
Income tax expense (benefit) | 31,514 | (423,662 | ) | |||||||||||
Net income | 419,826 | 0.47% | 1,144,013 | 1.40% | (63.3)% | |||||||||
Net loss attributable to noncontrolling interest | 961 | 5,295 | ||||||||||||
Net income attributable to AmerisourceBergen Corporation | $ | 420,787 | 0.47% | $ | 1,149,308 | 1.41% | (63.4)% | |||||||
Earnings per share: | ||||||||||||||
Basic | $ | 1.99 | $ | 5.25 | (62.1)% | |||||||||
Diluted | $ | 1.97 | $ | 5.19 | (62.0)% | |||||||||
Weighted average common shares outstanding: | ||||||||||||||
Basic | 211,503 | 218,763 | (3.3)% | |||||||||||
Diluted | 213,275 | 221,565 | (3.7)% | |||||||||||
________________________________________
1 | Includes a $139.3 million gain from antitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million reversal of a prior period assessment relating to the New York Opioid Stewardship Act in the six months ended March 31, 2019. Includes $22.5 million of PharMEDium remediation costs and a $0.3 million gain from antitrust litigation settlements in the six months ended March 31, 2018. |
2 | Includes $18.8 million of employee severance, $28.4 million of litigation costs primarily related to opioid lawsuits and investigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2019. Includes $28.4 million of employee severance, $10.4 million of litigation costs primarily related to opioid lawsuits, investigations, and initiatives, and $28.6 million of other costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2018. |
3 | Impairment of finite-lived intangible assets and property and equipment relating to PharMEDium. |
4 | Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019. Includes a $30.0 million impairment on a non-customer note receivable in the six months ended March 31, 2018. |
AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended March 31, 2019 | |||||||||||||||||||||||||||||||||
Gross Profit | Operating Expenses | Operating Income | Income Before Income Taxes | Income Tax (Benefit) Expense | Net Income Attributable to Noncontrolling Interest | Net Income Attributable to ABC | Diluted Earnings Per Share | ||||||||||||||||||||||||||
GAAP | $ | 1,424,756 | $ | 1,377,191 | $ | 47,565 | $ | 18,784 | $ | (9,289 | ) | $ | (938 | ) | $ | 27,135 | $ | 0.13 | |||||||||||||||
Gain from antitrust litigation settlements | (51,976 | ) | — | (51,976 | ) | (51,976 | ) | (16,980 | ) | — | (34,996 | ) | (0.16 | ) | |||||||||||||||||||
LIFO credit | (66,805 | ) | — | (66,805 | ) | (66,805 | ) | (17,137 | ) | — | (49,668 | ) | (0.23 | ) | |||||||||||||||||||
PharMEDium remediation costs | 12,334 | (3,563 | ) | 15,897 | 15,897 | 4,927 | — | 10,970 | 0.05 | ||||||||||||||||||||||||
New York State Opioid Stewardship Act | — | — | — | — | (944 | ) | — | 944 | — | ||||||||||||||||||||||||
Acquisition-related intangibles amortization | — | (46,594 | ) | 46,594 | 46,594 | 13,800 | (437 | ) | 32,357 | 0.15 | |||||||||||||||||||||||
Employee severance, litigation, and other | — | (55,389 | ) | 55,389 | 55,389 | 7,474 | — | 47,915 | 0.23 | ||||||||||||||||||||||||
Impairment of long-lived assets | — | (570,000 | ) | 570,000 | 570,000 | 145,103 | — | 424,897 | 2.00 | ||||||||||||||||||||||||
Gain on sale of an equity investment | — | — | — | (13,692 | ) | (3,485 | ) | — | (10,207 | ) | (0.05 | ) | |||||||||||||||||||||
Adjusted Non-GAAP | $ | 1,318,309 | $ | 701,645 | $ | 616,664 | $ | 574,191 | $ | 123,469 | $ | (1,375 | ) | $ | 449,347 | $ | 2.11 | 1 | |||||||||||||||
Adjusted Non-GAAP % change vs. prior year period | 3.2 | % | 1.5 | % | 5.2 | % | 6.6 | % | 10.9 | % | 4.0 | % | 8.8 | % | |||||||||||||||||||
Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
Gross profit | 3.29% | 3.04% | ||
Operating expenses | 3.18% | 1.62% | ||
Operating income | 0.11% | 1.42% | ||
________________________________________
1 | The sum of the components does not equal the total due to rounding. |
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended March 31, 2018 | ||||||||||||||||||||||||||||||||
Gross Profit | Operating Expenses | Operating Income | Income Before Income Taxes | Income Tax Expense | Net Loss Attributable to Noncontrolling Interest | Net Income Attributable to ABC | Diluted Earnings Per Share | |||||||||||||||||||||||||
GAAP | $ | 1,255,683 | $ | 774,263 | $ | 481,420 | $ | 361,332 | $ | 79,172 | $ | 5,295 | $ | 287,455 | $ | 1.29 | ||||||||||||||||
Gain from antitrust litigation settlements | (338 | ) | — | (338 | ) | (338 | ) | (97 | ) | — | (241 | ) | — | |||||||||||||||||||
PharMEDium remediation costs | 22,506 | — | 22,506 | 22,506 | 6,478 | — | 16,028 | 0.07 | ||||||||||||||||||||||||
Acquisition-related intangibles amortization | — | (45,295 | ) | 45,295 | 45,325 | 13,882 | (669 | ) | 30,774 | 0.14 | ||||||||||||||||||||||
Employee severance, litigation, and other | — | (37,449 | ) | 37,449 | 37,449 | 11,420 | — | 26,029 | 0.12 | |||||||||||||||||||||||
Loss on consolidation of equity investments | — | — | — | 42,328 | — | — | 42,328 | 0.19 | ||||||||||||||||||||||||
Impairment on non-customer note receivable | — | — | — | 30,000 | — | — | 30,000 | 0.13 | ||||||||||||||||||||||||
Loss on early retirement of debt | — | — | — | — | 507 | — | (507 | ) | — | |||||||||||||||||||||||
Adjusted Non-GAAP | $ | 1,277,851 | $ | 691,519 | $ | 586,332 | $ | 538,602 | $ | 111,362 | $ | 4,626 | $ | 431,866 | $ | 1.94 | ||||||||||||||||
Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
Gross profit | 3.06% | 3.11% | ||
Operating expenses | 1.89% | 1.69% | ||
Operating income | 1.17% | 1.43% | ||
________________________________________
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
(unaudited)
Six Months Ended March 31, 2019 | ||||||||||||||||||||||||||||||||
Gross Profit | Operating Expenses | Operating Income | Income Before Income Taxes | Income Tax Expense | Net Loss Attributable to Noncontrolling Interest | Net Income Attributable to ABC | Diluted Earnings Per Share | |||||||||||||||||||||||||
GAAP | $ | 2,722,336 | $ | 2,196,948 | $ | 525,388 | $ | 451,340 | $ | 31,514 | $ | 961 | $ | 420,787 | $ | 1.97 | ||||||||||||||||
Gain from antitrust litigation settlements | (139,255 | ) | — | (139,255 | ) | (139,255 | ) | (35,450 | ) | — | (103,805 | ) | (0.49 | ) | ||||||||||||||||||
LIFO credit | (69,834 | ) | — | (69,834 | ) | (69,834 | ) | (17,778 | ) | — | (52,056 | ) | (0.24 | ) | ||||||||||||||||||
PharMEDium remediation costs | 30,245 | (6,147 | ) | 36,392 | 36,392 | 9,264 | — | 27,128 | 0.13 | |||||||||||||||||||||||
New York State Opioid Stewardship Act | (22,000 | ) | — | (22,000 | ) | (22,000 | ) | (5,600 | ) | — | (16,400 | ) | (0.08 | ) | ||||||||||||||||||
Acquisition-related intangibles amortization | — | (91,746 | ) | 91,746 | 91,746 | 23,355 | (943 | ) | 67,448 | 0.32 | ||||||||||||||||||||||
Employee severance, litigation, and other | — | (96,061 | ) | 96,061 | 96,061 | 24,454 | — | 71,607 | 0.34 | |||||||||||||||||||||||
Impairment of long-lived assets | — | (570,000 | ) | 570,000 | 570,000 | 145,103 | — | 424,897 | 1.99 | |||||||||||||||||||||||
Gain on sale of an equity investment | — | — | — | (13,692 | ) | (3,485 | ) | — | (10,207 | ) | (0.05 | ) | ||||||||||||||||||||
Tax reform 1 | — | — | — | — | 36,997 | — | (36,997 | ) | (0.17 | ) | ||||||||||||||||||||||
Adjusted Non-GAAP | $ | 2,521,492 | $ | 1,432,994 | $ | 1,088,498 | $ | 1,000,758 | $ | 208,374 | $ | 18 | $ | 792,402 | $ | 3.72 | ||||||||||||||||
Adjusted Non-GAAP % change vs. prior year period | 5.5 | % | 8.9 | % | 1.3 | % | 1.0 | % | (5.7 | )% | 2.3 | % | 6.6 | % | ||||||||||||||||||
Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
Gross profit | 3.07% | 2.84% | ||
Operating expenses | 2.48% | 1.62% | ||
Operating income | 0.59% | 1.23% | ||
________________________________________
1 | Includes a measurement period adjustment to the one-time transition tax on historical foreign earnings and profits through December 31, 2017. |
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
(unaudited)
Six Months Ended March 31, 2018 | |||||||||||||||||||||||||||||||||
Gross Profit | Operating Expenses | Operating Income | Income Before Income Taxes | Income Tax (Benefit) Expense | Net Loss Attributable to Noncontrolling Interest | Net Income Attributable to ABC | Diluted Earnings Per Share | ||||||||||||||||||||||||||
GAAP | $ | 2,368,335 | $ | 1,467,942 | $ | 900,393 | $ | 720,351 | $ | (423,662 | ) | $ | 5,295 | $ | 1,149,308 | $ | 5.19 | ||||||||||||||||
Gain from antitrust litigation settlements | (338 | ) | — | (338 | ) | (338 | ) | (97 | ) | — | (241 | ) | — | ||||||||||||||||||||
PharMEDium remediation costs | 22,506 | — | 22,506 | 22,506 | 6,478 | — | 16,028 | 0.07 | |||||||||||||||||||||||||
Acquisition-related intangibles amortization | — | (84,351 | ) | 84,351 | 84,476 | 24,317 | (669 | ) | 59,490 | 0.27 | |||||||||||||||||||||||
Employee severance, litigation and other | — | (67,470 | ) | 67,470 | 67,470 | 19,421 | — | 48,049 | 0.22 | ||||||||||||||||||||||||
Loss on consolidation of equity investments | — | — | — | 42,328 | — | — | 42,328 | 0.19 | |||||||||||||||||||||||||
Impairment on non-customer note receivable | — | — | — | 30,000 | — | — | 30,000 | 0.14 | |||||||||||||||||||||||||
Loss on early retirement of debt | — | — | — | 23,766 | 6,841 | — | 16,925 | 0.08 | |||||||||||||||||||||||||
Tax Reform 1 | — | — | — | — | 587,595 | — | (587,595 | ) | (2.65 | ) | |||||||||||||||||||||||
Adjusted Non-GAAP | $ | 2,390,503 | $ | 1,316,121 | $ | 1,074,382 | $ | 990,559 | $ | 220,893 | $ | 4,626 | $ | 774,292 | $ | 3.49 | 2 | ||||||||||||||||
Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
Gross profit | 2.91% | 2.93% | ||
Operating expenses | 1.80% | 1.61% | ||
Operating income | 1.10% | 1.32% | ||
________________________________________
1 | Represents the impact of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017, offset in part by a one-time transition tax on historical foreign earnings and profits through December 31, 2017. |
2 | The sum of the components does not equal the total due to rounding. |
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
Three Months Ended March 31, | ||||||||||
Revenue | 2019 | 2018 | % Change | |||||||
Pharmaceutical Distribution Services | $ | 41,676,164 | $ | 39,453,353 | 5.6% | |||||
Other | 1,665,429 | 1,594,378 | 4.5% | |||||||
Intersegment eliminations | (21,991 | ) | (13,873 | ) | ||||||
Revenue | $ | 43,319,602 | $ | 41,033,858 | 5.6% | |||||
Three Months Ended March 31, | ||||||||||
Operating income | 2019 | 2018 | % Change | |||||||
Pharmaceutical Distribution Services | $ | 517,034 | $ | 489,106 | 5.7% | |||||
Other | 99,879 | 97,055 | 2.9% | |||||||
Intersegment eliminations | (249 | ) | 171 | |||||||
Total segment operating income | 616,664 | 586,332 | 5.2% | |||||||
Gain from antitrust litigation settlements | 51,976 | 338 | ||||||||
LIFO credit | 66,805 | — | ||||||||
PharMEDium remediation costs | (15,897 | ) | (22,506 | ) | ||||||
Acquisition-related intangibles amortization | (46,594 | ) | (45,295 | ) | ||||||
Employee severance, litigation, and other | (55,389 | ) | (37,449 | ) | ||||||
Impairment of long-lived assets | (570,000 | ) | — | |||||||
Operating income | $ | 47,565 | $ | 481,420 | ||||||
Percentages of revenue: | ||||||||||
Pharmaceutical Distribution Services | ||||||||||
Gross profit | 2.38% | 2.41% | ||||||||
Operating expenses | 1.14% | 1.17% | ||||||||
Operating income | 1.24% | 1.24% | ||||||||
Other | ||||||||||
Gross profit | 19.60% | 20.48% | ||||||||
Operating expenses | 13.60% | 14.39% | ||||||||
Operating income | 6.00% | 6.09% | ||||||||
AmerisourceBergen Corporation (GAAP) | ||||||||||
Gross profit | 3.29% | 3.06% | ||||||||
Operating expenses | 3.18% | 1.89% | ||||||||
Operating income | 0.11% | 1.17% | ||||||||
AmerisourceBergen Corporation (Non-GAAP) | ||||||||||
Adjusted gross profit | 3.04% | 3.11% | ||||||||
Adjusted operating expenses | 1.62% | 1.69% | ||||||||
Adjusted operating income | 1.42% | 1.43% | ||||||||
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
Six Months Ended March 31, | ||||||||||
Revenue | 2019 | 2018 | % Change | |||||||
Pharmaceutical Distribution Services | $ | 85,420,545 | $ | 78,391,051 | 9.0% | |||||
Other | 3,336,367 | 3,139,329 | 6.3% | |||||||
Intersegment eliminations | (44,858 | ) | (30,190 | ) | ||||||
Revenue | $ | 88,712,054 | $ | 81,500,190 | 8.8% | |||||
Six Months Ended March 31, | ||||||||||
Operating income | 2019 | 2018 | % Change | |||||||
Pharmaceutical Distribution Services | $ | 890,241 | $ | 877,288 | 1.5% | |||||
Other | 198,813 | 197,330 | 0.8% | |||||||
Intersegment eliminations | (556 | ) | (236 | ) | ||||||
Total segment operating income | 1,088,498 | 1,074,382 | 1.3% | |||||||
Gain from antitrust litigation settlements | 139,255 | 338 | ||||||||
LIFO credit | 69,834 | — | ||||||||
PharMEDium remediation costs | (36,392 | ) | (22,506 | ) | ||||||
New York State Opioid Stewardship Act | 22,000 | — | ||||||||
Acquisition-related intangibles amortization | (91,746 | ) | (84,351 | ) | ||||||
Employee severance, litigation, and other | (96,061 | ) | (67,470 | ) | ||||||
Impairment of long-lived assets | (570,000 | ) | — | |||||||
Operating income | $ | 525,388 | $ | 900,393 | ||||||
Percentages of revenue: | ||||||||||
Pharmaceutical Distribution Services | ||||||||||
Gross profit | 2.19% | 2.22% | ||||||||
Operating expenses | 1.15% | 1.11% | ||||||||
Operating income | 1.04% | 1.12% | ||||||||
Other | ||||||||||
Gross profit | 19.53% | 20.61% | ||||||||
Operating expenses | 13.57% | 14.32% | ||||||||
Operating income | 5.96% | 6.29% | ||||||||
AmerisourceBergen Corporation (GAAP) | ||||||||||
Gross profit | 3.07% | 2.91% | ||||||||
Operating expenses | 2.48% | 1.80% | ||||||||
Operating income | 0.59% | 1.10% | ||||||||
AmerisourceBergen Corporation (Non-GAAP) | ||||||||||
Adjusted gross profit | 2.84% | 2.93% | ||||||||
Adjusted operating expenses | 1.62% | 1.61% | ||||||||
Adjusted operating income | 1.23% | 1.32% | ||||||||
Note: For more information related to non-GAAP financial measures, refer to the section titled "Supplemental Information Regarding Non-GAAP Financial Measures" of this release.
AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
March 31, | September 30, | ||||||
2019 | 2018 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 2,875,750 | $ | 2,492,516 | |||
Accounts receivable, net | 12,222,271 | 11,314,226 | |||||
Inventories | 11,373,730 | 11,918,508 | |||||
Right to recover asset 1 | 977,860 | — | |||||
Prepaid expenses and other | 172,572 | 169,122 | |||||
Total current assets | 27,622,183 | 25,894,372 | |||||
Property and equipment, net | 1,858,867 | 1,892,424 | |||||
Goodwill and other intangible assets | 9,055,678 | 9,612,100 | |||||
Other long-term assets | 273,582 | 270,942 | |||||
Total assets | $ | 38,810,310 | $ | 37,669,838 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 28,189,390 | $ | 26,836,873 | |||
Other current liabilities | 1,022,509 | 1,032,814 | |||||
Total current liabilities | 29,211,899 | 27,869,687 | |||||
Long-term debt | 4,009,500 | 4,158,532 | |||||
Accrued income taxes | 273,662 | 299,600 | |||||
Deferred income taxes | 1,857,201 | 1,829,410 | |||||
Other long-term liabilities | 419,717 | 462,648 | |||||
Total equity | 3,038,331 | 3,049,961 | |||||
Total liabilities and equity | $ | 38,810,310 | $ | 37,669,838 | |||
1 Right to recover assets represents the inventory value associated with the accrual for estimated customer sales returns. The inventories balance at September 30, 2018 includes a $988.8 million accrual for estimated customer sales returns.
AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Six Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Operating Activities: | |||||||
Net income | $ | 419,826 | $ | 1,144,013 | |||
Adjustments to reconcile net income to net cash provided by (used in) operating activities 1, 2 | 820,403 | (414,709 | ) | ||||
Changes in operating assets and liabilities, excluding the effects of acquisitions: | |||||||
Accounts receivable | (880,805 | ) | (590,386 | ) | |||
Inventories | (420,190 | ) | (805,164 | ) | |||
Accounts payable | 1,350,728 | 384,378 | |||||
Other 3 | (186,630 | ) | 204,626 | ||||
Net cash provided by (used in) operating activities | 1,103,332 | (77,242 | ) | ||||
Investing Activities: | |||||||
Capital expenditures | (161,488 | ) | (168,816 | ) | |||
Cost of acquired companies, net of cash acquired | (52,398 | ) | (777,085 | ) | |||
Other | 2,659 | 10,479 | |||||
Net cash used in investing activities | (211,227 | ) | (935,422 | ) | |||
Financing Activities: | |||||||
Net (repayments) borrowings 4 | (16,017 | ) | 820,724 | ||||
Payment of premium on early retirement of debt | — | (22,348 | ) | ||||
Purchases of common stock 5 | (347,959 | ) | (60,208 | ) | |||
Exercises of stock options | 37,590 | 115,236 | |||||
Cash dividends on common stock | (170,428 | ) | (167,533 | ) | |||
Other | (12,057 | ) | (16,963 | ) | |||
Net cash (used in) provided by financing activities | (508,871 | ) | 668,908 | ||||
Increase (decrease) in cash and cash equivalents | 383,234 | (343,756 | ) | ||||
Cash and cash equivalents at beginning of period | 2,492,516 | 2,435,115 | |||||
Cash and cash equivalents at end of period | $ | 2,875,750 | $ | 2,091,359 | |||
________________________________________
1 | Adjustments include a LIFO credit of $69.8 million and an impairment of long-lived assets of $570.0 million for the six months ended March 31, 2019. |
2 | Includes a $798.4 million benefit for deferred income taxes for the six months ended March 31, 2018, primarily as a result of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017 in connection with tax reform. |
3 Includes a $262.5 million increase in income taxes payable for the six months ended March 31, 2018, primarily as a result of a one-time transition tax on historical foreign earnings and profits through December 31, 2017 in connection with tax reform.
4 Net borrowings for the six months ended March 31, 2018 were primarily used to finance the acquisition of H.D. Smith, which was completed on January 2, 2018.
5 Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of September 2018 purchases that cash settled in October 2018.
SUPPLEMENTAL INFORMATION REGARDING
NON-GAAP FINANCIAL MEASURES
To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP. These supplemental measures may vary from, and may not be comparable to, similarly titled measures by other companies.
The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the Company’s operating performance, to perform financial planning, and to determine incentive compensation. Therefore, the Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. The presented non-GAAP financial measures exclude items that management does not believe reflect the Company’s core operating performance because such items are outside the control of the Company or are inherently unusual, non-operating, unpredictable, non-recurring, or non-cash. We have included the following non-GAAP earnings-related financial measures in this release:
• | Adjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the gain from antitrust litigation settlements, certain PharMEDium remediation costs, LIFO expense (credit), and costs (credit) related to the New York State Opioid Stewardship Act. Gain from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items. PharMEDium remediation costs are excluded because they are unpredictable expenses. The costs (credit) related to the New York State Opioid Stewardship Act are excluded because they are unusual, non-recurring and non-cash. Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the Company’s ongoing operating performance. The gain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities following U.S. Food and Drug Administration inspections. LIFO expense (credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences. The New York State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York state. In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the U.S. District for the Southern District of New York. |
• | Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial measure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain PharMEDium remediation costs, and impairment of long-lived assets. Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of the acquired companies. We exclude employee severance amounts that relate to unpredictable and/or non-recurring business restructuring. We exclude the amount of litigation settlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational performance. |
• | Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial measure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted operating expenses. Adjusted operating income margin is the ratio of adjusted operating income to total revenue. Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the Company’s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature. |
• | Adjusted income before income taxes: Adjusted income before income taxes is a non-GAAP financial measure that excludes the same items that are described above and excluded from adjusted operating income. In addition, the gain on sale of an equity investment in fiscal 2019, the loss on consolidation of equity investments in fiscal 2018, the impairment on non-customer note receivable in fiscal 2018, and the loss on the early retirement of debt in fiscal 2018 are also excluded from adjusted income before income taxes because these amounts are unusual, non-operating, or non-recurring. Management believes that this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company’s adjusted effective tax rate. |
• | Adjusted effective tax rate: Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted income tax expense/benefit by adjusted income before income taxes. Management believes that this non-GAAP financial measure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company. |
• | Adjusted income tax expense (benefit): Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax expense (benefit) associated with the same items that are described above and excluded from adjusted income before income taxes. In addition, the one-time U.S. tax reform ("Tax Reform") adjustments are excluded from adjusted income tax expense. Tax Reform includes a benefit, and any measurement period adjustments, from applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017, offset in part by a one-time transition tax on historical foreign earnings and profits through December 31, 2017. Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company’s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature. |
• | Adjusted net income (loss) attributable to noncontrolling interest: Adjusted net income attributable to noncontrolling interest excludes the non-controlling interest portion of acquisition-related intangibles amortization. Management believes that this non-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC. |
• | Adjusted net income attributable to ABC: Adjusted net income attributable to ABC is a non-GAAP financial measure that excludes the same items that are described above. Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature. |
• | Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments including gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; costs (credit) related to the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation, and other; gain on sale of an equity investment; impairment of long-lived assets; the loss on consolidation of equity investments; the impairment on non-customer note receivable; and the loss on early retirement of debt; in each case net of the tax effect calculated using the applicable effective tax rate for those items. In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share. Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. |
In addition, the Company has provided non-GAAP fiscal year 2019 guidance for diluted earnings per share, operating expense, operating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring or non-cash in nature. In addition, it has provided fiscal year 2019 adjusted free cash flow guidance. For fiscal year 2019, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures. The Company does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company’s control, and acquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.
Contacts: Bennett S. Murphy
Vice President, Investor Relations
610-727-3693
bmurphy@amerisourcebergen.com
###